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To the Editor:
Up to 80% of CML patients using tyrosine kinase inhibitors
(TKIs) reports muscle complaints [1]. These muscle com-
plaints are strongly related to the presence of fatigue and
contributes to both diminished disease control [2] and
impaired quality of life [3]. Although the mechanism by
which TKIs cause muscle complaints is poorly understood,
mitochondrial dysfunction has been suggested to play a
pivotal role in TKI-induced cardiac muscle toxicity [4, 5].
We assessed whether TKIs disturb skeletal muscle mito-
chondrial density and function (cellular level), and if
this translates into alterations in muscle contractile function
(muscle tissue level) and maximal exercise
performance (whole-body level). To gain a better insight
into TKI-induced muscle complaints, these outcomes were
compared between CML patients with and without muscle
complaints. Written informed consent was obtained from
the participants prior to study enrollment. This study was
approved by the Local Committee on Research Involving
Human Subjects of the region Arnhem and Nijmegen,
the Netherlands and registered at The Netherlands Trial
Registry (NTR6373).
A total of twenty Ph+ CP-CML patients on TKI therapy
aged ≥ 18 were recruited from the Department of Hematol-
ogy at the Radboud University Medical Center (Nijmegen,
The Netherlands). CML patients were assigned to a group
with (CML+MC, N= 10) or without (CML -MC, N= 10)
muscle complaints (MC) on the basis of presence, onset and
course of muscle cramps, pain, and/or weakness. This was
quantified on a Likert scale from 1 (not at all) to 4
(very much) resulting in significant different scores between
CML+MC and CML -MC (median 4.0 (interquartile
range (IQR) 3.0–4.0) and 2.5 (IQR 2.0–3.0), respectively;
P= 0.002). The Brief Fatigue Inventory (BFI) [6] was used
to compare the degree of fatigue in CML patients, showing
higher fatigue levels in CML+MC when compared to
CML -MC (3.58 ± 2.19 and 0.95 ± 1.11, respectively; P=
0.005). Ten control participants were matched on group
level for age, gender, BMI and physical activity level,
assessed by The Short Questionnaire to Assess Health-
Enhancing Physical Activity (SQUASH) [7]. Subjects were
ineligible if they had hereditary muscle defects, diabetes
mellitus, hypo- or hyperthyroidism, severe electrolyte dis-
turbances, or used co-medication known to cause muscle
symptoms or have an effect on mitochondrial function
(e.g. statins, steroids, and metformin). Furthermore, subjects
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with contra-indications for maximal exercise testing
according to the ACC/AHA guidelines [8] and muscle
biopsy (e.g. anticoagulant therapy, bleeding disorders) were
excluded. The demographic and hematological character-
istics shown in Table 1 are not statistically significant dif-
ferent between CML patients and controls and between
CML+MC and CML -MC, except for a higher Charlson
Comorbidity Index [9] score in CML patients when com-
pared to controls (median 2.0 (IQR 2.0–2.0) and 0.0 (IQR
0.0–0.0), respectively; P < 0.001) caused by the presence
of CML. All participants completed the study protocol,
i.e. a vastus lateralis muscle biopsy, electrical quadriceps
femoris stimulations, and an incremental cycling test.
Vastus lateralis muscle needle biopsies were performed
under local anesthesia in overnight fasted state and processed
for mitochondrial measurements according to standard lab
techniques as previously published [10]. Citrate synthase
activity, a marker for mitochondrial density, was not different
between CML patients and controls (195 ± 80mU/mg pro-
tein and 171 ± 30mU/mg protein, respectively, P= 0.24)
and between CML+MC and CML -MC (P= 0.33).
Furthermore, mitochondrial function, assessed by ATP pro-
duction capacity (Fig. 1a, c) and [1-14C]-pyruvate oxidation
rates in the presence of malate or carnitine (Fig. 1b, d) was
not different between groups.
Maximal voluntary muscle strength of the dominant
quadriceps femoris muscle [11], did neither differ between
CML patients and controls (8.3 ± 2.0N/kg and 7.9 ± 1.8 N/kg,
respectively; P= 0.59), nor between CML+MC and
CML-MC (P= 0.97). Resistance to fatigue was assessed by
electrically stimulating the quadriceps femoris muscle
repetitively at 40% of the MVC using 30 Hz bursts of one-
second duration every other second for two minutes [11].
This fatigue protocol resulted in a significantly larger force
decline in CML patients as compared to controls (31.8 ±
8.7% and 23.6 ± 7.7%, respectively; P= 0.010; Fig. 1e).
Although a similar fatigability pattern was observed
between CML+MC and CML -MC (force decline 29 ±
9% and 34 ± 9%, respectively; P= 0.24), the contractile
properties of the quadriceps femoris muscle during
repeated stimulation were explored in more detail. After
two minutes of stimulation CML+MC showed a
Table 1 Subject and hematological characteristics
Characteristics CML patients Controls P value CML+MC CML -MC P value
Subject number, N 20 10 – 10 10 –
Gender, male/female 14/6 7/3 1.00 7/3 7/3 1.00
Age, years 54 ± 8 58 ± 7 0.25 55 ± 9 54 ± 8 0.86
BMI, kg/m2 25.8 ± 4.1 27.5 ± 5.4 0.34 25.8 ± 3.6 25.8 ± 4.8 0.97
Physical activity, METmin/week; median (IQR) 2288 (1545–4982) 2850 (1965–4868) 0.53 2541 (1689–5488) 2070 (1403–4570) 0.63
Smoker, % 0 0 – 0 0 –
Age at Dx, years 46 ± 8 N/A – 47 ± 7 46 ± 9 0.78
BCR-ABL level, N (%) N/A – 1.00
No MMR 1 (5) 1 (10) 0 (0)
MMR or deeper 19 (95%) 9 (90) 10 (100)
TKI, N (%) – 0.89
Imatinib 10 (50) N/A 6 (60) 4 (40)
Dasatinib 5 (25) N/A 2 (20) 3 (30)
Nilotinib 2 (10) N/A 1 (10) 1 (10)
Bosutinib 2 (10) N/A 1 (10) 1 (10)
Ponatinib 1 (5) N/A 0 (0) 1 (10)
Duration of current TKI therapy, months; median (IQR) 42.5 (21.0–114.8) N/A – 66.5 (19.0–121.5) 38.0 (16.5–73.3) 0.63
Prior TKIs, N; median (IQR) 0.5 (0.0–1.0) N/A – 0.0 (0.0–1.0) 1.0 (0.0–1.0) 0.53
Charslon Comorbidity Index; median (IQR) 2.0 (2.0–2.0) 0.0 (0.0–0.0) <0.001 2.0 (2.0–2.0) 2.0 (2.0–2.0) 0.74
Potassium, mmol/l 3.9 ± 0.28 4.0 ± 0.20 0.50 3.9 ± 0.21 4.0 ± 0.34 0.76
Magnesium, mmol/l 0.82 ± 0.06 0.84 ± 0.06 0.49 0.82 ± 0.05 0.83 ± 0.06 0.63
Phosphate, mmol/l 0.82 ± 0.12 0.91 ± 0.17 0.11 0.83 ± 0.10 0.81 ± 0.15 0.75
Calcium, mmol/l 2.29 ± 0.09 2.30 ± 0.06 0.68 2.29 ± 0.09 2.29 ± 0.10 0.91
Albumin, g/l 38.7 ± 2.5 37.3 ± 2.0 0.13 39.1 ± 2.8 38.3 ± 2.2 0.48
TSH, mE/l; median (IQR) 2.1 (1.4–2.6) 2.0 (1.3–2.8) 0.90 2.0 (0.8–2.9) 2.1 (1.5–2.7) 0.61
CK, U/l; median (IQR) 137 (89–236) 120 (109–166) 0.61 169 (103–312) 127 (84–216) 0.90
Values are presented as mean ± SD unless indicated otherwise. There were no significant differences in subject and hematological characteristics
between CML patients, except for a higher Charslon Comorbidity Index score in CML patients Also, there were no significant differences between
CML patients with and without TKI induced muscle complaints
MC muscle complaints, BMI body mass index, MET metabolic equivalent of task, IQR interquartile range, Dx diagnosis, MMR major molecular
response, TKI tyrosine kinase inhibitor, TSH thyroid-stimulating hormone, CK creatine kinase
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Fig. 1 Skeletal muscle mitochondrial function and muscle function
parameters measured in CML patients and controls. a ATP production
rate normalized to muscle protein content and (b) [1-14C]-pyruvate
oxidation rates in the presence of malate and carnitine normalized to
muscle protein content measured in mitochondrial fractions from fresh
vastus lateralis muscle biopsies were not affected by TKI use. There
were also no differences in (c) ATP production rate and (d) [1-14C]-
pyruvate oxidation rates in the presence of malate and carnitine
between CML+MC and CML -MC. e Force decline expressed as
percentage of the prefatigue value during two minutes repetitive
electrical stimulation of the quadriceps femoris muscle shows a higher
level of muscle fatigue in CML patients compared to controls. Force
responses are plotted every second during the complete (120 sec)
fatigue protocol. f Maximal force rise after two minutes of electrical
quadriceps femoris stimulation was significantly lower in CML+MC
when compared to CML -MC. g Quadriceps femoris muscle in
CML+MC showed a tendency toward longer relaxation time
after two minute repetitive stimulation when compared to CML -MC.
h Reported fatigue by CML patients (assessed by the Brief Fatigue
Inventory) correlates with half relaxation time in quadriceps femoris
muscle after two minutes repetitive electrical stimulation (N= 15).
Data are presented as means ± SEM for a–d; and means ± SD for e–g.
*P value < 0.05 is considered statistically significant
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significantly lower maximal force rise (maximal slope
of force increment normalized for peak force) compared
to CML -MC (0.54 ± 0.10%/ms and 0.67 ± 0.13%/ms,
respectively; P= 0.038; Fig. 1f) and a tendency toward
longer half relaxation time (time taken for force to decline
from 50 to 25% of the peak force; P= 0.07; Fig. 1g). The
half relaxation time at the end of the fatigue protocol
strongly correlated with reported fatigue (rp= 0.72; P=
0.002; Fig. 1h). Since muscle relaxation is dependent upon
the activity of sarco/endoplasmic reticulum Ca2+-ATPase
(SERCA), an enzyme that mediates the re-uptake of cal-
cium into the sarcoplasmic reticulum (SR) of skeletal
muscle, SERCA activity was measured in whole-muscle
homogenates [11]. However, no significant differences in
SERCA activity were observed between CML+MC and
CML -MC (98.9 (IQR 79.3–110.7 mU/mg) and 101.5 (IQR
77.0–109.8 mU/mg), respectively; P= 0.97).
To measure whole-body fitness levels, all subjects per-
formed an incremental cycle ergometer test (Lode Excali-
bur; Groningen, the Netherlands) with continuous ECG
monitoring [10] to assess peak oxygen uptake (VO2peak).
VO2peak was 34.6 ± 8.4 ml/kg/min (100 ± 9% predicted) in
the CML patients, which was not different from the controls
(VO2peak 35.6 ± 7.5 ml/kg/min, 100 ± 9% predicted; P=
0.75). In addition, no differences in VO2peak were observed
between CML+MC and CML -MC (P= 0.38).
Collectively, CML patients on TKI therapy show no signs
of skeletal muscle mitochondrial dysfunction. However,
quadriceps femoris muscle of TKI users fatigues to a larger
extent upon repetitive stimulation when compared to con-
trols. Changes in muscle contractile properties are associated
with TKI-induced muscle complaints, as CML+MC show
a significant lower maximal force rise and a tendency toward
a delayed muscle relaxation after two minutes of electrical
quadriceps femoris stimulations. CML patients did not have
impaired maximal exercise performance.
On a cellular level, no effects of TKI therapy on skeletal
muscle mitochondrial density and function were found. These
results are in line with the only previous clinical case report in
which two CML patients, who had to interrupt or reduce
therapy with nilotinib because of muscle pain, failed to show
disturbances in mitochondrial oxidative enzyme reactions
[12]. Intriguingly, in vitro studies in C2C12 myotubes
showed no decline in ATP levels upon short-term imatinib
incubation of 30min [13], whereas long-term TKI-incubation
of 24 h showed decreased ATP levels overtime [5, 13].
Disturbances in heart mitochondrial function are sug-
gested to occur secondary to activation of a stress response
in the endoplasmic reticulum [4]. Perhaps, in skeletal
muscle, changes in the function of other cellular organelles
also precede mitochondrial disturbances. In support of this
hypothesis, CML patients on TKI therapy showed sig-
nificantly more muscle fatigue than controls, and CML+
MC showed delayed quadriceps femoris muscle force
generation and a trend toward delayed relaxation in fatigued
muscle compared to CML -MC. Since muscle fatigability,
force generation, and relaxation are largely dependent on
Ca2+ regelulation by the SR, changes in SR functioning
may underlie these findings [14]. In that respect, dis-
turbances in Ca2+ homeostasis [15], and SR abnormalities
(i.e., dilated SR with membrane whorls) [4] have been
found upon imatinib treatment in myocytes, but have never
been linked to muscle complaints. Although we found no
difference in SERCA activity between CML+MC and
CML -MC, muscle half relaxation time after 2-min stimu-
lation correlated positively with the perception of fatigue in
CML patients, and may therefore be an important key for
understanding the mechanism underlying fatigue in CML.
To the best of our knowledge, maximal exercise capacity
has not been assessed before in CML patients or other TKI-
users. Compared to controls, CML patients do not have
diminished maximal exercise capacity as measured by
VO2peak and have similar physical activity levels as controls.
VO2peak was also not different between CML+MC
and CML -MC, despite higher subjective fatigue levels in
CML+MC. These findings fit with the unaltered mito-
chondrial ATP production capacity, which is an important
determinant of VO22peak.
There are several limitations to this study. Due to the
exploratory character of the study a relatively large number of
measurements were performed in a small sample size.
Therefore, results should be cautiously interpreted. None-
theless, this design made it possible to examine the influence
of TKIs on multiple levels (i.e. cellular, muscle tissue and
whole body level) which offers broad insight into the effects
of TKIs in CML patients. Secondly, participants were only
included when they were able to perform all study measure-
ments. Thus patients who were unable to perform exercise
testing were excluded. Consequently, extreme cases of TKI-
induced skeletal muscle complaints were not included in this
study, which may have underestimated the results.
This study provides important information concerning
the effects of TKIs on skeletal muscle function and whole
body fitness and lays foundation for further studies to elu-
cidate the precise mechanism by which TKI therapy causes
muscle complaints and affects muscle function.
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